Spero Therapeutics (NASDAQ: SPRO) doubles share authorization and adopts 2026 stock plan
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Spero Therapeutics, Inc. held its 2026 annual meeting of stockholders, where stockholders approved a new 2026 Stock Incentive Plan covering up to 12,895,866 shares of common stock. This plan will be used for future equity awards to employees, directors, and other service providers.
Stockholders also approved an amendment to the Amended and Restated Certificate of Incorporation to increase authorized common stock from 120,000,000 shares to 240,000,000 shares, expanding the capacity for future issuances. A quorum of 41,061,190 shares, or about 70.91% of the 57,901,493 shares outstanding as of April 24, 2026, was present, and director nominees and other proposals received the required support.
Positive
- None.
Negative
- None.
Insights
Spero expands equity capacity with a new incentive plan and doubled authorized shares.
Spero Therapeutics gained stockholder approval for a 2026 Stock Incentive Plan covering up to 12,895,866 shares and doubled its authorized common stock to 240,000,000 shares. This combination increases flexibility to grant equity compensation and potentially raise capital through future share issuances.
These actions do not themselves issue new shares but set the framework for future dilution as awards are granted or capital raises occur. The annual meeting was well attended, with about 70.91% of 57,901,493 shares outstanding as of April 24, 2026 counted toward quorum, and director elections and proposals received strong support.
8-K Event Classification
4 items: 5.02, 5.03, 5.07, 9.01
4 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
2026 Plan share pool: 12,895,866 shares
Authorized common stock after amendment: 240,000,000 shares
Authorized common stock before amendment: 120,000,000 shares
+4 more
7 metrics
2026 Plan share pool
12,895,866 shares
Maximum shares issuable under 2026 Stock Incentive Plan
Authorized common stock after amendment
240,000,000 shares
Total authorized common stock under amended charter
Authorized common stock before amendment
120,000,000 shares
Authorized common stock prior to June 23, 2026 amendment
Shares outstanding on record date
57,901,493 shares
Common stock issued and outstanding as of April 24, 2026
Quorum shares present
41,061,190 shares
Shares present in person or by proxy at annual meeting
Quorum percentage
70.91%
Portion of outstanding shares represented at annual meeting
Votes for key proposal
40,866,196 votes
One proposal vote total For, with 189,300 Against and 5,694 Abstained
Key Terms
2026 Stock Incentive Plan, Amended and Restated Certificate of Incorporation, Broker Non-Votes, quorum, +1 more
5 terms
2026 Stock Incentive Plan financial
"stockholders approved the Spero Therapeutics, Inc. 2026 Stock Incentive Plan (the “2026 Plan”)"
Amended and Restated Certificate of Incorporation regulatory
"approved an amendment to the Company’s Amended and Restated Certificate of Incorporation"
A company’s amended and restated certificate of incorporation is an updated version of its foundational legal charter that replaces the older document and folds in all changes into one clear copy; it spells out corporate structure, classes of stock, shareholder rights and key governance rules. Investors care because it can change who controls the company, how votes are counted, what claims shareholders have on assets or dividends, and can introduce or remove protections against takeovers—like updating a house title after a major renovation to show who owns what and under what rules.
Broker Non-Votes financial
"Votes For | | Votes Against | | Votes Abstained | | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
quorum financial
"a quorum of 41,061,190 shares, or approximately 70.91% of the outstanding shares, were present"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
Certificate of Amendment regulatory
"The certificate of amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”)"
A certificate of amendment is an official filing that updates a company’s founding documents—its legal “rulebook” that sets share structure, voting rules, name and basic purpose. Think of it like changing the blueprint of a building: small changes are paperwork, big ones can alter who owns how much and who controls decisions. Investors watch these filings because they can affect share counts, voting power, dilution and company value.
FAQ
What did Spero Therapeutics (SPRO) stockholders approve at the 2026 annual meeting?
Stockholders approved the 2026 Stock Incentive Plan and an amendment doubling authorized common stock to 240,000,000 shares. They also elected directors and passed other proposals with the necessary voting support.
What was the quorum at Spero Therapeutics' 2026 annual meeting?
A quorum of 41,061,190 shares, representing approximately 70.91% of the 57,901,493 shares outstanding as of April 24, 2026, was present. This satisfied requirements to conduct official stockholder business.
Were Spero Therapeutics director nominees elected at the 2026 annual meeting?
Yes. Director nominees, including Milind Deshpande, Ph.D., and Kathleen Tregoning, received more votes "For" than "Withheld". Broker non-votes were recorded but did not prevent their election to the board.
What proposals besides the stock plan and charter amendment did SPRO investors vote on?
Investors voted on director elections and additional proposals summarized by vote totals, including 40,866,196 votes "For" on one item and 30,356,780 votes "For" on another, indicating broad support across the agenda.